{"disease":{"id":"purpura-thrombocytopenic-idiopathic","name":"purpura thrombocytopenic idiopathic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03252457","title":"Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT03443570","title":"Rituximab Combining Bortezomib Versus Rituximab in Management of ITP","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT01762761","title":"Eltrombopag Phase III Study In Chinese Chronic ITP Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05506033","title":"Optimization of Glucocorticoid Taper Strategies for SLE-ITP","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT05438875","title":"The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03258866","title":"The Study of Different Dose Rituximab in the Treatment of ITP","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT02281370","title":"Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03275454","title":"A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT02201290","title":"A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02009761","title":"Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}